|
1
|
Durie BG, Kyle RA, Belch A, Bensinger W,
Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D,
et al: Scientific Advisors of the International Myeloma Foundation:
Myeloma management guidelines: A consensus report from the
Scientific Advisors of the International Myeloma Foundation.
Hematol J. 4:379–398. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kyle RA, Durie BG, Rajkumar SV, Landgren
O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos
M, et al: International Myeloma Working Group: Monoclonal
gammopathy of undetermined significance (MGUS) and smoldering
(asymptomatic) multiple myeloma: IMWG consensus perspectives risk
factors for progression and guidelines for monitoring and
management. Leukemia. 24:1121–1127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aritaka N, Ichikawa K, Nakamura H, Yasuda
H, Ogura K, Matsumoto T, Komatsu N and Hirano T: Attainment of a
stringent complete response in multiple myeloma with thalidomide
monotherapy. Intern Med. 51:2781–2783. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moustafa M Alhaj, Rajkumar SV, Dispenzieri
A, Gertz MA, Lacy MQ, Buadi FK, Hwa YL, Dingli D, Kapoor P, Hayman
SR, et al: Utility of serum free light chain measurements in
multiple myeloma patients not achieving complete response to
therapy. Leukemia. 29:2033–2038. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Katzmann JA, Kyle RA, Benson J, Larson DR,
Snyder MR, Lust JA, Rajkumar SV and Dispenzieri A: Screening panels
for detection of monoclonal gammopathies. Clin Chem. 55:1517–1522.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Murray DL, Ryu E, Snyder MR and Katzmann
JA: Quantitation of serum monoclonal proteins: Relationship between
agarose gel electrophoresis and immunonephelometry. Clin Chem.
55:1523–1529. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bradwell AR, Carr-Smith HD, Mead GP, Tang
LX, Showell PJ, Drayson MT and Drew R: Highly sensitive, automated
immunoassay for immunoglobulin free light chains in serum and
urine. Clin Chem. 47:673–680. 2001.PubMed/NCBI
|
|
8
|
Dispenzieri A, Kyle R, Merlini G, Miguel
JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S,
et al: International Myeloma Working Group: International Myeloma
Working Group guidelines for serum-free light chain analysis in
multiple myeloma and related disorders. Leukemia. 23:215–224. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rajkumar SV, Harousseau JL, Durie B,
Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski
R, Siegel D, et al: International Myeloma Workshop Consensus Panel
1: Consensus recommendations for the uniform reporting of clinical
trials: Report of the International Myeloma Workshop Consensus
Panel I. Blood. 117:4691–4695. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rajkumar SV, Dimopoulos MA, Palumbo A,
Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E,
Richardson P..et al: International Myeloma Working Group updated
criteria for the diagnosis of multiple myeloma. Lancet Oncol.
15:e538–e548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bradwell AR, Harding SJ, Fourrier NJ,
Wallis GLF, Drayson MT, Carr-Smith HD and Mead GP: Assessment of
monoclonal gammopathies by nephelometric measurement of individual
immunoglobulin kappa/lambda ratios. Clin Chem. 55:1646–1655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guidelines Working Group of UK Myeloma
Forum, . British Committee for Standards in Haematology, British
Society for Haematology: Guidelines on the diagnosis and management
of AL amyloidosis. Br J Haematol. 125:681–700. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bird J, Behrens J, Westin J, Turesson I,
Drayson M, Beetham R, D'Sa S, Soutar R, Waage A, Gulbrandsen N, et
al: Haemato-oncology Task Force of the British Committee for
Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study
Group: UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group
(NMSG): Guidelines for the investigation of newly detected
M-proteins and the management of monoclonal gammopathy of
undetermined significance (MGUS). Br J Haematol. 147:22–42. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dimopoulos MA, Kyle R, Fermand JP,
Rajkumar SV, Miguel J San, Chanan-Khan A, Ludwig H, Joshua D, Mehta
J, Gertz M, et al: International Myeloma Workshop Consensus Panel
3: Consensus recommendations for standard investigative workup:
Report of the International Myeloma Workshop Consensus Panel 3.
Blood. 117:4701–4705. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mead GP, Carr-Smith HD, Drayson MT, Morgan
GJ, Child JA and Bradwell AR: Serum free light chains for
monitoring multiple myeloma. Br J Haematol. 126:348–354. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Siegel D, Bilotti E and van Hoeven KH:
Serum free light chain analysis for diagnosis, monitoring, and
prognosis of monoclonal gammopathies. Lab Med. 40:363–366. 2009.
View Article : Google Scholar
|
|
17
|
Smith A, Wisloff F and Samson D: UK
Myeloma Forum; Nordic Myeloma Study Group; British Committee for
Standards in Haematology: Guidelines on the diagnosis and
management of multiple myeloma 2005. Br J Haematol. 132:410–451.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Donato LJ, Zeldenrust SR, Murray DL and
Katzmann JA: A 71-year-old woman with multiple myeloma status after
stem cell transplantation. Clin Chem. 57:1645–1648. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fulton RB and Fernando SL: Serum free
light chain assay reduces the need for serum and urine
immunofixation electrophoresis in the evaluation of monoclonal
gammopathy. Ann Clin Biochem. 46:407–412. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vernocchi A, Gelsumini S and Piazza E:
Prevalence of the monoclonal gammopathy of undetermined
significance (MGUS) in out-patients >50 years old: An indication
to carry out electrophoresis of serum protein? Biochim Clin.
38:154–155. 2014.
|
|
21
|
Gertz MA: Utility of the immunoglobulin
free light chain assay for plasma cell disorders 2015. Leuk
Lymphoma. 56:2757–2758. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bradwell AR, Carr-Smith HD, Mead GP,
Harvey TC and Drayson MT: Serum test for assessment of patients
with Bence Jones myeloma. Lancet. 361:489–491. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Drayson M, Tang LX, Drew R, Mead GP,
Carr-Smith H and Bradwell AR: Serum free light-chain measurements
for identifying and monitoring patients with nonsecretory multiple
myeloma. Blood. 97:2900–2902. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brioli A, Giles H, Pawlyn C, Campbell JP,
Kaiser MF, Melchor L, Jackson GH, Gregory WM, Owen RG, Child JA, et
al: Serum free immunoglobulin light chain evaluation as a marker of
impact from intraclonal heterogeneity on myeloma outcome. Blood.
123:3414–3419. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Katzmann JA and Rajkumar SV: A window into
immunoglobulin quantitation and plasma cell disease: Antigen
epitopes defined by the junction of immunoglobulin heavy and light
chains. Leukemia. 27:1–2. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ludwig H, Milosavljevic D, Zojer N, Faint
JM, Bradwell AR, Hübl W and Harding SJ: Immunoglobulin heavy/light
chain ratios improve paraprotein detection and monitoring, identify
residual disease and correlate with survival in multiple myeloma
patients. Leukemia. 27:213–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lakomy D, Lemaire-Ewing S, Denimal D,
Bastie JN, Lafon I and Caillot D: Evaluation of the new Hevylite™
IgA assay for the diagnosis and follow-up of monoclonal
gammopathies. Ann Biol Clin (Paris). 71:157–163. 2013.(In French).
PubMed/NCBI
|
|
28
|
Keren DF: Heavy/light-chain analysis of
monoclonal gammopathies. Clin Chem. 55:1606–1608. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Astolfi M, Omedè P, Redoglia V, Oddolo D,
Ferrero MP and Ciaiolo C: Simultaneous evaluation of serum Hevylite
and Freelite assays for relapse prediction in multiple myeloma.
Biochim Clin. 37:383–388. 2013.
|
|
30
|
Bhutani M, Landgren O and Usmani SZ:
Multiple myeloma: Is it time for biomarker-driven therapy? Am Soc
Clin Oncol Educ Book. 35:e493–e503. 2015. View Article : Google Scholar
|
|
31
|
Landgren O and Morgan GJ: Biologic
frontiers in multiple myeloma: From biomarker identification to
clinical practice. Clin Cancer Res. 20:804–813. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Paolini L, Di Noto G, Maffina F,
Martellosio G, Radeghieri A, Luigi C and Ricotta D: Comparison of
Hevylite™ IgA and IgG assay with conventional techniques for the
diagnosis and follow-up of plasma cell dyscrasia. Ann Clin Biochem.
52:337–345. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Katzmann JA, Willrich MA, Kohlhagen MC,
Kyle RA, Murray DL, Snyder MR, Rajkumar SV and Dispenzieri A:
Monitoring IgA multiple myeloma: Immunoglobulin heavy/light chain
assays. Clin Chem. 61:360–367. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bradwell A, Harding S, Fourrier N, Mathiot
C, Attal M, Moreau P, Harousseau JL and Avet-Loiseau H: Prognostic
utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple
myeloma patients. Leukemia. 27:202–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Koulieris E, Panayiotidis P, Harding SJ,
Kafasi N, Maltezas D, Bartzis V, Tzenou T, Dimou M, Georgiou G,
Mirbahai L, et al: Ratio of involved/uninvolved immunoglobulin
quantification by Hevylite™ assay: Clinical and prognostic impact
in multiple myeloma. Exp Hematol Oncol. 1:92012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rajkumar SV, Landgren O and Mateos MV:
Smoldering multiple myeloma. Blood. 125:3069–3075. 2015. View Article : Google Scholar : PubMed/NCBI
|
